Publications by authors named "Denys Tsybulskyi"
Ann Surg Oncol
January 2025
Article Synopsis
- - The study analyzed how changes in chemotherapy based on CA19-9 levels during neoadjuvant therapy (NAT) impact outcomes for patients with pancreatic ductal adenocarcinoma (PDAC).
- - Results from 283 patients showed that those who received a chemotherapy change (particularly those who achieved the desired CA19-9 reduction) had significantly better overall survival compared to those who did not have a chemotherapy change.
- - The findings suggest that adjusting chemotherapy based on CA19-9 levels can enhance treatment outcomes for patients with resectable or borderline resectable PDAC, highlighting the importance of personalized treatment approaches.
Article Synopsis
- New treatment strategies for unresectable pancreatic ductal adenocarcinoma (UR-M PDAC) are emerging, including the use of maintenance therapy with olaparib after chemotherapy, particularly for patients with BRCA mutations.
- A 47-year-old male patient diagnosed with PDAC and confirmed BRCA2 mutation underwent 16 weeks of triple chemotherapy, followed by 14 weeks of olaparib, leading to normalization of tumor markers and disappearance of liver metastases.
- Following successful chemotherapy, the patient was able to have laparoscopic surgery to remove the tumor, and he has remained cancer-free for 27 months post-surgery, highlighting the potential for long-term survival with this treatment approach.
J Gastrointest Oncol
December 2023
Article Synopsis
- The study evaluates the effectiveness of conversion surgery for patients with liver-only synchronous metastases of pancreatic ductal adenocarcinoma who responded positively to chemotherapy, comparing outcomes with other treatment methods.
- A total of 49 patients were analyzed, divided into three groups: those who had conversion surgery (10), upfront surgery (8), and those who only received chemotherapy (31).
- Results showed that the conversion surgery group had significantly better median survival times (36.7 months) compared to the chemotherapy group (9.9 months) and the upfront surgery group (10.4 months), highlighting the potential benefit of conversion surgery for selected patients.
